Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2016-09-09

Clinical Trial Update: Efficacy and Safety Study of MSRD-100 in Subjects With Atopic Dermatitis >=3 Months of Age and Older [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating MSRD-100 for atopic dermatitis was withdrawn, and the trial is no longer active.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MSRD-100

Snippet

Sponsor: Merz North America, Inc. | Conditions: Atopic Dermatitis | Phase 3 | Status: WITHDRAWN